Cargando…

Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder

We have recently reported sex differences in the plasma concentrations of lysophosphatidic acid (LPA) and alterations in LPA species in patients with alcohol and cocaine use disorders. Preclinical evidence suggests a main role of lysophosphatidic acid (LPA) signaling in anxiogenic responses and drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Requena-Ocaña, Nerea, Flores-López, María, García-Marchena, Nuria, Pavón-Morón, Francisco J., Pedraza, Carmen, Wallace, Agustín, Castilla-Ortega, Estela, Rodríguez de Fonseca, Fernando, Serrano, Antonia, Araos, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649657/
https://www.ncbi.nlm.nih.gov/pubmed/37958570
http://dx.doi.org/10.3390/ijms242115586
_version_ 1785135602518196224
author Requena-Ocaña, Nerea
Flores-López, María
García-Marchena, Nuria
Pavón-Morón, Francisco J.
Pedraza, Carmen
Wallace, Agustín
Castilla-Ortega, Estela
Rodríguez de Fonseca, Fernando
Serrano, Antonia
Araos, Pedro
author_facet Requena-Ocaña, Nerea
Flores-López, María
García-Marchena, Nuria
Pavón-Morón, Francisco J.
Pedraza, Carmen
Wallace, Agustín
Castilla-Ortega, Estela
Rodríguez de Fonseca, Fernando
Serrano, Antonia
Araos, Pedro
author_sort Requena-Ocaña, Nerea
collection PubMed
description We have recently reported sex differences in the plasma concentrations of lysophosphatidic acid (LPA) and alterations in LPA species in patients with alcohol and cocaine use disorders. Preclinical evidence suggests a main role of lysophosphatidic acid (LPA) signaling in anxiogenic responses and drug addiction. To further explore the potential role of the LPA signaling system in sex differences and psychiatric comorbidity in cocaine use disorder (CUD), we conducted a cross-sectional study with 88 patients diagnosed with CUD in outpatient treatment and 60 healthy controls. Plasma concentrations of total LPA and LPA species (16:0, 18:0, 18:1, 18:2 and 20:4) were quantified and correlated with cortisol and tryptophan metabolites [tryptophan (TRP), serotonin (5-HT), kynurenine (KYN), quinolinic acid (QUIN) and kynurenic acid (KYNA)]. We found sexual dimorphism for the total LPA and most LPA species in the control and CUD groups. The total LPA and LPA species were not altered in CUD patients compared to the controls. There was a significant correlation between 18:2 LPA and age at CUD diagnosis (years) in the total sample, but total LPA, 16:0 LPA and 18:2 LPA correlated with age at onset of CUD in male patients. Women with CUD had more comorbid anxiety and eating disorders, whereas men had more cannabis use disorders. Total LPA, 18:0 LPA and 20:4 LPA were significantly decreased in CUD patients with anxiety disorders. Both 20:4 LPA and total LPA were significantly higher in women without anxiety disorders compared to men with and without anxiety disorders. Total LPA and 16:0 LPA were significantly decreased in CUD patients with childhood ADHD. Both 18:1 LPA and 20:4 LPA were significantly augmented in CUD patients with personality disorders. KYNA significantly correlated with total LPA, 16:0 LPA and 18:2 LPA species, while TRP correlated with the 18:1 LPA species. Our results demonstrate that LPA signaling is affected by sex and psychiatric comorbidity in CUD patients, playing an essential role in mediating their anxiety symptoms.
format Online
Article
Text
id pubmed-10649657
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106496572023-10-25 Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder Requena-Ocaña, Nerea Flores-López, María García-Marchena, Nuria Pavón-Morón, Francisco J. Pedraza, Carmen Wallace, Agustín Castilla-Ortega, Estela Rodríguez de Fonseca, Fernando Serrano, Antonia Araos, Pedro Int J Mol Sci Article We have recently reported sex differences in the plasma concentrations of lysophosphatidic acid (LPA) and alterations in LPA species in patients with alcohol and cocaine use disorders. Preclinical evidence suggests a main role of lysophosphatidic acid (LPA) signaling in anxiogenic responses and drug addiction. To further explore the potential role of the LPA signaling system in sex differences and psychiatric comorbidity in cocaine use disorder (CUD), we conducted a cross-sectional study with 88 patients diagnosed with CUD in outpatient treatment and 60 healthy controls. Plasma concentrations of total LPA and LPA species (16:0, 18:0, 18:1, 18:2 and 20:4) were quantified and correlated with cortisol and tryptophan metabolites [tryptophan (TRP), serotonin (5-HT), kynurenine (KYN), quinolinic acid (QUIN) and kynurenic acid (KYNA)]. We found sexual dimorphism for the total LPA and most LPA species in the control and CUD groups. The total LPA and LPA species were not altered in CUD patients compared to the controls. There was a significant correlation between 18:2 LPA and age at CUD diagnosis (years) in the total sample, but total LPA, 16:0 LPA and 18:2 LPA correlated with age at onset of CUD in male patients. Women with CUD had more comorbid anxiety and eating disorders, whereas men had more cannabis use disorders. Total LPA, 18:0 LPA and 20:4 LPA were significantly decreased in CUD patients with anxiety disorders. Both 20:4 LPA and total LPA were significantly higher in women without anxiety disorders compared to men with and without anxiety disorders. Total LPA and 16:0 LPA were significantly decreased in CUD patients with childhood ADHD. Both 18:1 LPA and 20:4 LPA were significantly augmented in CUD patients with personality disorders. KYNA significantly correlated with total LPA, 16:0 LPA and 18:2 LPA species, while TRP correlated with the 18:1 LPA species. Our results demonstrate that LPA signaling is affected by sex and psychiatric comorbidity in CUD patients, playing an essential role in mediating their anxiety symptoms. MDPI 2023-10-25 /pmc/articles/PMC10649657/ /pubmed/37958570 http://dx.doi.org/10.3390/ijms242115586 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Requena-Ocaña, Nerea
Flores-López, María
García-Marchena, Nuria
Pavón-Morón, Francisco J.
Pedraza, Carmen
Wallace, Agustín
Castilla-Ortega, Estela
Rodríguez de Fonseca, Fernando
Serrano, Antonia
Araos, Pedro
Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder
title Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder
title_full Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder
title_fullStr Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder
title_full_unstemmed Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder
title_short Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder
title_sort plasma lysophosphatidic acid concentrations in sex differences and psychiatric comorbidity in patients with cocaine use disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649657/
https://www.ncbi.nlm.nih.gov/pubmed/37958570
http://dx.doi.org/10.3390/ijms242115586
work_keys_str_mv AT requenaocananerea plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder
AT floreslopezmaria plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder
AT garciamarchenanuria plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder
AT pavonmoronfranciscoj plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder
AT pedrazacarmen plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder
AT wallaceagustin plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder
AT castillaortegaestela plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder
AT rodriguezdefonsecafernando plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder
AT serranoantonia plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder
AT araospedro plasmalysophosphatidicacidconcentrationsinsexdifferencesandpsychiatriccomorbidityinpatientswithcocaineusedisorder